Pharmacokinetics and bioequivalence studies of galantamine hydrobromide dispersible tablet in healthy male Chinese volunteers

Drug Development and Industrial Pharmacy

Volumn 33, Issue 3, 2007, Pages 335-340

  Zhang, Li Jun ^a   Fang, Xiao Ling ^a   Li, Xue Ning ^a   Wang, Qing Song ^a   Han, Li Mei ^a   Zhang, Zhi Wen ^a   Sha, Xian Yi ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Bioequivalence; Galantamine; High performance liquid chromatography; Pharmacokinetics

Indexed keywords

GALANTAMINE; TRAMADOL;

ADULT; AMPLIFIER; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CHINESE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISPERSIBLE TABLET; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LINEAR SYSTEM; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TABLET FORMULATION; UNSPECIFIED SIDE EFFECT; VOLUNTEER;

ADULT; AREA UNDER CURVE; CHINA; CHOLINESTERASE INHIBITORS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; GALANTAMINE; HUMANS; MALE; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 34247487380     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040600868011     Document Type: Article

References (9)

1. Coyle, J. & Kershaw, P. (2001). Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biol. Psych., 49, 289-299.
2. Erkinjuntti, T. (2002). Treatment options: the latest evidence with galantamine (Reminyl®). J. Neurol. Sci., 203-204, 125-130.
3. Farlow, M. R. (2001). Pharmacokinetic profiles of current therapies for Alzheimer's disease: implication for switching to galantamine. Clinic Therap., 23 suppl A, 13-24.
4. Huang, F. L., Lasseter, K. C., Janssens, L., Verhaeghe, T., Lau, H., & Zhao, Q. (2002). Pharmacokinetic and safety assessments of galantamine and Risperidone after the two drugs are administrated alone and together. J. Clin. Pharmacol., 42, 1341-1351.
5. Migliaccio-Walle, K., Getsios, D., Caro, J. J., Ishak, K. J., O'Brien, J. A., & Papadopoulos, G. (2003). Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States. Clinic. Therap., 25, 1806-1825.
6. Standridge, J. B. (2004). Pharmacotherapeutic approaches to the treatment of Alzheimer's disease. Clinic. Therap., 26, 615-630.
7. Suh, G. H., Yeon Jung, H., UK Lee, C., Hoon Oh, B., Nam Bae, J., Jung, H. Y., Ju, Y. S., Kil Yeon, B., Park, J., Hong, I., Choi, S., & Ho Lee, J. (2004). A prospective, double-blind, community controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population. Clinic. Therap., 26, 1608-1618.
8. Verhaeghe, T., Diels, L., Vries de, R., De Mevlder, M., & De Jong, J. (2003). Development and validation of a liquid chromatographictandem mass spectrometric method for the determination of galantamine in human heparinised plasma. J. Chromatogr. B, 789, 337-346.
9. Zhao, Q. Y., Brett, M., Van Osselaer, N., Huang, F., Raoult, A., Van Peer, A., Verhaeghe, T., & Hust, R. (2002). Galantamine pharmacokinetics, safety, and tolerability profiles are similar in healthy Caucasian and Japanese subjects. J. Clin. Pharmacol., 42, 1002-1010.